Patents by Inventor David Igel
David Igel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9101772Abstract: A method of stimulation therapy and an apparatus for providing the therapy which addresses cardiac dysfunction including heart failure. The therapy employs atrial pacing pulses delivered to a heart after the atrial refractory period and timed so that they will not cause a ventricular contraction. These atrial pacing are timed to achieve beneficial effects on myocardial mechanics (efficacy) while maintaining an extremely low level of risk of arrhythmia induction. These methods may be employed individually or in combinations in an external or implantable ESS therapy delivery device.Type: GrantFiled: December 9, 2009Date of Patent: August 11, 2015Assignee: Medtronic, Inc.Inventors: Karen J. Kleckner, Kathleen A. Prieve, Jeffrey M. Gillberg, Ren Zhou, Kenneth M. Anderson, D. Curtis Deno, Glenn C. Zillmer, Ruth N. Klepfer, Vincent E. Splett, David E. Euler, Lawrence J. Mulligan, Edwin G. Duffin, David A. Igel, John E. Burnes
-
Patent number: 9042982Abstract: Methods and devices for determining optimal Atrial to Ventricular (AV) pacing intervals and Ventricular to Ventricular (VV) delay intervals in order to optimize cardiac output. Impedance, preferably sub-threshold impedance, is measured across the heart at selected cardiac cycle times as a measure of chamber expansion or contraction. One embodiment measures impedance over a long AV interval to obtain the minimum impedance, indicative of maximum ventricular expansion, in order to set the AV interval. Another embodiment measures impedance change over a cycle and varies the AV pace interval in a binary search to converge on the AV interval causing maximum impedance change indicative of maximum ventricular output. Another method varies the right ventricle to left ventricle (VV) interval to converge on an impedance maximum indicative of minimum cardiac volume at end systole. Another embodiment varies the VV interval to maximize impedance change.Type: GrantFiled: February 20, 2012Date of Patent: May 26, 2015Assignee: Medtronic, Inc.Inventors: John E. Burnes, Yong K. Cho, David Igel, Luc R. Mongeon, John C. Rueter, Harry Stone, Jodi Zilinski
-
Publication number: 20120303084Abstract: The above-described methods and apparatus are believed to be of particular benefit for patients suffering heart failure including cardiac dysfunction, chronic HF, and the like and all variants as described herein and including those known to those of skill in the art to which the invention is directed. It will understood that the present invention offers the possibility of monitoring and therapy of a wide variety of acute and chronic cardiac dysfunctions. The current invention provides systems and methods for delivering therapy for cardiac hemodynamic dysfunction via the innervated myocardial substrate receives one or more discrete pulses of electrical stimulation during the refractory period of said innervated myocardial substrate.Type: ApplicationFiled: August 8, 2012Publication date: November 29, 2012Applicant: Medtronic, Inc.Inventors: Karen J. Kleckner, Kathleen A. Prieve, Jeffrey M. Gillberg, Ren Zhou, Kenneth M. Anderson, D. Curtis Deno, Glenn C. Zillmer, Ruth N. Klepfer, Vincent E. Splett, David E. Euler, Lawrence J. Mulligan, Edwin G. Duffin, David A. Igel, John E. Burnes
-
Publication number: 20120150253Abstract: Methods and devices for determining optimal Atrial to Ventricular (AV) pacing intervals and Ventricular to Ventricular (VV) delay intervals in order to optimize cardiac output. Impedance, preferably sub-threshold impedance, is measured across the heart at selected cardiac cycle times as a measure of chamber expansion or contraction. One embodiment measures impedance over a long AV interval to obtain the minimum impedance, indicative of maximum ventricular expansion, in order to set the AV interval. Another embodiment measures impedance change over a cycle and varies the AV pace interval in a binary search to converge on the AV interval causing maximum impedance change indicative of maximum ventricular output. Another method varies the right ventricle to left ventricle (VV) interval to converge on an impedance maximum indicative of minimum cardiac volume at end systole. Another embodiment varies the VV interval to maximize impedance change.Type: ApplicationFiled: February 20, 2012Publication date: June 14, 2012Applicant: Medtronic, Inc.Inventors: John E. Burnes, Yong K. Cho, David Igel, Luc R. Mongeon, John C. Rueter, Harry Stone, Jodi Zilinski
-
Patent number: 8135463Abstract: Methods and devices for determining optimal Atrial to Ventricular (AV) pacing intervals and Ventricular to Ventricular (VV) delay intervals in order to optimize cardiac output. Impedance, preferably sub-threshold impedance, is measured across the heart at selected cardiac cycle times as a measure of chamber expansion or contraction. One embodiment measures impedance over a long AV interval to obtain the minimum impedance, indicative of maximum ventricular expansion, in order to set the AV interval. Another embodiment measures impedance change over a cycle and varies the AV pace interval in a binary search to converge on the AV interval causing maximum impedance change indicative of maximum ventricular output. Another method varies the right ventricle to left ventricle (VV) interval to converge on an impedance maximum indicative of minimum cardiac volume at end systole. Another embodiment varies the VV interval to maximize impedance change.Type: GrantFiled: May 21, 2007Date of Patent: March 13, 2012Assignee: Medtronic, Inc.Inventors: John E. Burnes, Yong K. Cho, David Igel, Luc R. Mongeon, John C. Rueter, Harry Stone, Jodi Zilinski
-
Publication number: 20100210954Abstract: A system and method for cardiovascular analysis includes an implantable medical device capable of generating hemodynamic pressure waveform data based upon sensed pressure. Hemodynamic waveform data is analyzed to identify artifactual data represented in the hemodynamic waveform.Type: ApplicationFiled: April 28, 2010Publication date: August 19, 2010Applicant: Medtronic, Inc.Inventors: Tommy D. BENNETT, Mark CHOI, David A. IGEL, Michael R.S. HILL, Teresa A. WHITMAN
-
Publication number: 20100152804Abstract: The above-described methods and apparatus are believed to be of particular benefit for patients suffering heart failure including cardiac dysfunction, chronic HF, and the like and all variants as described herein and including those known to those of skill in the art to which the invention is directed. It will understood that the present invention offers the possibility of monitoring and therapy of a wide variety of acute and chronic cardiac dysfunctions. The current invention provides systems and methods for delivering therapy for cardiac hemodynamic dysfunction via the innervated myocardial substrate receives one or more discrete pulses of electrical stimulation during the refractory period of said innervated myocardial substrate.Type: ApplicationFiled: December 9, 2009Publication date: June 17, 2010Applicant: Medtronic, Inc.Inventors: Karen J. Kleckner, Kathleen A. Prieve, Jeffrey M. Gillberg, Ren Zhou, Kenneth M. Anderson, D. Curtis Deno, Glenn C. Zillmer, Ruth N. Klepfer, Vincent E. Splett, David E. Euler, Lawrence J. Mulligan, Edwin G. Duffin, David A. Igel, John E. Burnes
-
Patent number: 7711423Abstract: Impedance, e.g. sub-threshold impedance, is measured across the heart at selected cardiac cycle times as a measure of chamber expansion or contraction. One embodiment measures impedance over a long AV interval to obtain the minimum impedance, indicative of maximum ventricular expansion, in order to set the AV interval. Another embodiment measures impedance change over a cycle and varies the AV pace interval in a binary search to converge on the AV interval causing maximum impedance change indicative of maximum ventricular output. Another method varies the right ventricle to left ventricle (VV) interval to converge on an impedance maximum indicative of minimum cardiac volume at end systole. Another embodiment varies the VV interval to maximize impedance change. Other methods vary the AA interval to maximize impedance change over the entire cardiac cycle or during the atrial cycle.Type: GrantFiled: May 24, 2005Date of Patent: May 4, 2010Assignee: Medtronic, Inc.Inventors: John E. Burnes, David A. Igel, John C. Rueter, Yong K. Cho, Luc R. Mongeon, Harold E. Stone, Jodi Zilinski
-
Patent number: 7708693Abstract: A system and method for cardiovascular analysis includes an implantable medical device capable of generating hemodynamic pressure waveform data based upon sensed pressure. Hemodynamic waveform data is analyzed to identify artifactual data represented in the hemodynamic waveform.Type: GrantFiled: January 27, 2005Date of Patent: May 4, 2010Assignee: Medtronic, Inc.Inventors: Tommy D. Bennett, Mark Choi, David A. Igel, Michael R. S. Hill, Teresa A. Whitman
-
Patent number: 7367951Abstract: A cardiovascular analysis system and method includes an implantable medical device with a sensor positioned to sense a hemodynamic pressure over time. The implantable medical device generates hemodynamic pressure waveform data based upon the hemodynamic pressure sensed. A processor analyzes the hemodynamic waveform data to provide an indication of cardiovascular health based upon prominent peaks in the hemodynamic waveform data.Type: GrantFiled: January 27, 2005Date of Patent: May 6, 2008Assignee: Medtronic, Inc.Inventors: Tommy D. Bennett, Mark Choi, David A. Igel, Michael R. S. Hill, Teresa A. Whitman, Douglas A. Hettrick
-
Publication number: 20070299477Abstract: The above-described methods and apparatus are believed to be of particular benefit for patients suffering heart failure including cardiac dysfunction, chronic HF, and the like and all variants as described herein and including those known to those of skill in the art to which the invention is directed. It will understood that the present invention offers the possibility of monitoring and therapy of a wide variety of acute and chronic cardiac dysfunctions. The current invention provides systems and methods for delivering therapy for cardiac hemodynamic dysfunction via the innervated myocardial substrate receives one or more discrete pulses of electrical stimulation during the refractory period of said innervated myocardial substrate.Type: ApplicationFiled: June 19, 2007Publication date: December 27, 2007Inventors: Karen Kleckner, Kathleen Prieve, Jeffrey Gillberg, Ren Zhou, Kenneth Anderson, D. Deno, Glenn Zillmer, Ruth Klepfer, Vincent Splett, David Euler, Lawrence Mulligan, Edwin Duffin, David Igel, John Burnes
-
Patent number: 7292888Abstract: A medical device, e.g., an implantable medical device, delivers one or more neurally-excitable stimulation pulses to myocardial tissue during a period when the tissue is refractory. The width of the pulses is less than or equal to approximately one half millisecond. In some embodiments, the current amplitude of the pulses is less than or equal to approximately twenty milliamps. In exemplary embodiments, the medical device delivers a pulse train of six or fewer pulses separated from each other by an interval that is greater than or equal to approximately ten milliseconds. In some embodiments, the medical device delivers pulses according to a schedule stored in a memory, or as a function of a monitored physiological parameter of a patient, such as an intracardiac pressure. In some embodiments, the medical device suspends or withholds delivery of neurally-excitable based on detection of cardiac ischemia.Type: GrantFiled: August 11, 2003Date of Patent: November 6, 2007Assignee: Medtronic, Inc.Inventors: D. Curtis Deno, David E. Euler, Lawrence J. Mulligan, Edwin G. Duffin, David A. Igel
-
Publication number: 20070213778Abstract: Methods and devices for determining optimal Atrial to Ventricular (AV) pacing intervals and Ventricular to Ventricular (VV) delay intervals in order to optimize cardiac output. Impedance, preferably sub-threshold impedance, is measured across the heart at selected cardiac cycle times as a measure of chamber expansion or contraction. One embodiment measures impedance over a long AV interval to obtain the minimum impedance, indicative of maximum ventricular expansion, in order to set the AV interval. Another embodiment measures impedance change over a cycle and varies the AV pace interval in a binary search to converge on the AV interval causing maximum impedance change indicative of maximum ventricular output. Another method varies the right ventricle to left ventricle (VV) interval to converge on an impedance maximum indicative of minimum cardiac volume at end systole. Another embodiment varies the VV interval to maximize impedance change.Type: ApplicationFiled: May 21, 2007Publication date: September 13, 2007Inventors: John Burnes, Yong Cho, David Igel, Luc Mongeon, John Rueter, Harry Stone, Jody Zilinski
-
Patent number: 7228174Abstract: Methods and devices for determining optimal Atrial to Ventricular (AV) pacing intervals and Ventricular to Ventricular (VV) delay intervals in order to optimize cardiac output. Impedance, preferably sub-threshold impedance, is measured across the heart at selected cardiac cycle times as a measure of chamber expansion or contraction. One embodiment measures impedance over a long AV interval to obtain the minimum impedance, indicative of maximum ventricular expansion, in order to set the AV interval. Another embodiment measures impedance change over a cycle and varies the AV pace interval in a binary search to converge on the AV interval causing maximum impedance change indicative of maximum ventricular output. Another method varies the right ventricle to left ventricle (VV) interval to converge on an impedance maximum indicative of minimum cardiac volume at end systole. Another embodiment varies the VV interval to maximize impedance change.Type: GrantFiled: April 29, 2002Date of Patent: June 5, 2007Assignee: Medtronics, Inc.Inventors: John E. Burnes, Yong K. Cho, David Igel, Luc R. Mongeon, John C. Rueter, Harry Stone, Jodi Zilinski
-
Publication number: 20060271117Abstract: Impedance, e.g. sub-threshold impedance, is measured across the heart at selected cardiac cycle times as a measure of chamber expansion or contraction. One embodiment measures impedance over a long AV interval to obtain the minimum impedance, indicative of maximum ventricular expansion, in order to set the AV interval. Another embodiment measures impedance change over a cycle and varies the AV pace interval in a binary search to converge on the AV interval causing maximum impedance change indicative of maximum ventricular output. Another method varies the right ventricle to left ventricle (VV) interval to converge on an impedance maximum indicative of minimum cardiac volume at end systole. Another embodiment varies the VV interval to maximize impedance change. Other methods vary the AA interval to maximize impedance change over the entire cardiac cycle or during the atrial cycle.Type: ApplicationFiled: May 24, 2005Publication date: November 30, 2006Inventors: John Burnes, David Igel, John Rueter, Yong Cho, Luc Mongeon, Harold Stone, Jodi Zilinski
-
Publication number: 20060167360Abstract: A system and method for cardiovascular analysis includes an implantable medical device capable of generating hemodynamic pressure waveform data based upon sensed pressure. Hemodynamic waveform data is analyzed to identify artifactual data represented in the hemodynamic waveform.Type: ApplicationFiled: January 27, 2005Publication date: July 27, 2006Inventors: Tommy Bennett, Mark Choi, David Igel, Michael Hill, Teresa Whitman
-
Publication number: 20060167359Abstract: A cardiovascular analysis system and method includes an implantable medical device with a sensor positioned to sense a hemodynamic pressure over time. The implantable medical device generates hemodynamic pressure waveform data based upon the hemodynamic pressure sensed. A processor analyzes the hemodynamic waveform data to provide an indication of cardiovascular health based upon prominent peaks in the hemodynamic waveform data.Type: ApplicationFiled: January 27, 2005Publication date: July 27, 2006Inventors: Tommy Bennett, Mark Choi, David Igel, Michael Hill, Teresa Whitman, Douglas Hettrick
-
Publication number: 20050038479Abstract: A medical device, e.g., an implantable medical device, delivers one or more neurally-excitable stimulation pulses to myocardial tissue during a period when the tissue is refractory. The width of the pulses is less than or equal to approximately one half millisecond. In some embodiments, the current amplitude of the pulses is less than or equal to approximately twenty milliamps. In exemplary embodiments, the medical device delivers a pulse train of six or fewer pulses separated from each other by an interval that is greater than or equal to approximately ten milliseconds. In some embodiments, the medical device delivers pulses according to a schedule stored in a memory, or as a function of a monitored physiological parameter of a patient, such as an intracardiac pressure. In some embodiments, the medical device suspends or withholds delivery of neurally-excitable based on detection of cardiac ischemia.Type: ApplicationFiled: August 11, 2003Publication date: February 17, 2005Inventors: D. Deno, David Euler, Lawrence Mulligan, Edwin Duffin, David Igel
-
Patent number: 6738667Abstract: An implantable stimulator and monitor measures a group of heart failure parameters indicative of the state of heart failure employing EGM signals, measures of blood pressure including absolute pressure P, developed pressure (DP=systolic P−diastolic P), and/or dP/dt, and measures of heart chamber volume (V) over one or more cardiac cycles. These parameters include: (1) relaxation or contraction time constant tau (&tgr;); (2) mechanical restitution (MR), i.e., the mechanical response of a heart chamber to premature stimuli applied to the heart chamber; (3) recirculation fraction (RF), i.e., the rate of decay of PESP effects over a series of heart cycles; and (4) end systolic elastance (EES), i.e., the ratios of end systolic blood pressure P to volume V. These heart failure parameters are determined periodically regardless of patient posture and activity level.Type: GrantFiled: December 28, 2000Date of Patent: May 18, 2004Assignee: Medtronic, Inc.Inventors: D. Curtis Deno, Lawrence J. Mulligan, Tom D. Bennett, David A. Igel, Michael R. S. Hill, Richard J. Shaw
-
Publication number: 20030204212Abstract: Methods and devices for determining optimal Atrial to Ventricular (AV) pacing intervals and Ventricular to Ventricular (VV) delay intervals in order to optimize cardiac output. Impedance, preferably sub-threshold impedance, is measured across the heart at selected cardiac cycle times as a measure of chamber expansion or contraction. One embodiment measures impedance over a long AV interval to obtain the minimum impedance, indicative of maximum ventricular expansion, in order to set the AV interval. Another embodiment measures impedance change over a cycle and varies the AV pace interval in a binary search to converge on the AV interval causing maximum impedance change indicative of maximum ventricular output. Another method varies the right ventricle to left ventricle (VV) interval to converge on an impedance maximum indicative of minimum cardiac volume at end systole. Another embodiment varies the VV interval to maximize impedance change.Type: ApplicationFiled: April 29, 2002Publication date: October 30, 2003Inventors: John E. Burnes, Yong K. Cho, David Igel, Luc R. Mongeon, John C. Rueter, Harry Stone, Jodi Zilinski